HYFT

MindWalk Holdings Corp

Jun 02 • 04:00PM ET

1.97

+0.23 13.22 %

Healthcare • Biotechnology • USA • Micro • NASD

Today, 7:25 AMMindWalk preclinical dengue data show HYFT-designed immunogens generated cross-reactive antibodies to all four dengue serotypes

Peers: BYSI CING ESLA EXOZ FBIO IBIO IBO IMA IMMP PDSB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.19	Insider Own	9.33%	Shs Outstand	46.71M	Perf Week	20.86%
Market Cap	92.02M	Forward P/E	-	EPS next Y	-0.18	Insider Trans	0.00%	Shs Float	42.36M	Perf Month	62.81%
Enterprise Value	84.23M	PEG	-	EPS next Q	-0.05	Inst Own	9.68%	Short Float	1.55%	Perf Quarter	79.09%
Income	-8.81M	P/S	6.98	EPS this Y	66.22%	Inst Trans	-0.04%	Short Ratio	1.76	Perf Half Y	-4.37%
Sales	13.18M	P/B	8.39	EPS next Y	16.84%	ROA	-39.85%	Short Interest	0.66M	Perf YTD	8.24%
Book/sh	0.23	P/C	8.86	EPS next 5Y	42.79%	ROE	-68.13%	52W High	3.25 -39.31%	Perf Year	244.77%
Cash/sh	0.22	P/FCF	-	EPS past 3/5Y	1.32% -19.06%	ROIC	-66.43%	52W Low	0.50 294.00%	Perf 3Y	-36.97%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	4.47% 10.84%	Gross Margin	59.70%	Volatility	9.77% 10.07%	Perf 5Y	-74.06%
Dividend TTM	-	EV/Sales	6.39	EPS Y/Y TTM	83.13%	Oper. Margin	-66.10%	ATR (14)	0.16	Perf 10Y	10002.56%
Dividend Ex-Date	-	Quick Ratio	3.64	Sales Y/Y TTM	-24.34%	Profit Margin	-66.84%	RSI (14)	74.75	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.74	EPS Q/Q	86.80%	SMA20	34.65%	Beta	0.82	Target Price	4.30
Payout	-	Debt/Eq	0.24	Sales Q/Q	-30.80%	SMA50	52.15%	Rel Volume	1.83	Prev Close	1.74
Employees	102	LT Debt/Eq	0.21	Earnings	Mar 12 BMO	SMA200	17.71%	Avg Volume	372.66K	Price	1.97
IPO	Nov 06, 2003	Option/Short	Yes / Yes	EPS/Sales Surpr.	-48.86% -9.28%	Trades		Volume	681,009	Change	13.22%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-22	Initiated	H.C. Wainwright	Buy	$9
Oct-25-21	Initiated	The Benchmark Company	Buy	$12

Today 07:20AM	MindWalk's Preclinical Dengue Data Support a HYFT Computational Prediction: Immunogens Designed on the Predicted Target Elicited Cross-Reactive Antibodies Against Antigens of All Four Dengue Serotypes, Reproduced Across Two Independent Campaigns (Business Wire) +13.22%
May-27-26 08:00AM	MindWalk Holdings Deploys Pandemic Response Platform via HYFT Technology as Ebola and Hantavirus Outbreaks Expose the Limits of Strain-Specific Coverage (Business Wire)
May-18-26 08:34AM	The Biology Came First. (Business Wire) +5.88%
Mar-12-26 05:02PM	MindWalk Holdings Corp (HYFT) Q3 2026 Earnings Call Highlights: Revenue Surge and Strategic Shifts (GuruFocus.com) -5.34%
12:44PM	MindWalk Holdings Corp. Q3 2026 Earnings Call Summary (Moby)
08:31AM	Loading…
08:31AM	MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results (Business Wire)
Mar-10-26 09:00AM	Stagwell (STGW) Q4 Earnings and Revenues Top Estimates (Zacks) +18.18%
Mar-06-26 04:01PM	MindWalk Announces B Cell Llama, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era (Business Wire) -5.13%
Mar-02-26 08:31AM	MindWalk Holdings Corp. to Report Third Quarter Fiscal Year 2026 Financial Results on March 12, 2026 (Business Wire)
Jan-27-26 12:01AM	MindWalk Applies HYFT Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics (Business Wire)
Jan-14-26 08:00AM	MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease (Business Wire) -12.30%
Jan-12-26 07:00AM	REPEAT/MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight (Business Wire)
Jan-09-26 08:01PM	MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight (Business Wire)
Dec-15-25 06:00PM	MindWalk Holdings Corp (HYFT) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) -6.15%
09:45AM	MindWalk Holdings Corp. (HYFT) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
08:30AM	Loading…
08:30AM	MindWalk Reports Record Growth and Announces Strategic Progress on Its AI Asset Pipeline (Business Wire)
Dec-08-25 08:30AM	MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2026 on December 15, 2025 (Business Wire)
Dec-03-25 08:15AM	Sprinklr (CXM) Q3 Earnings and Revenues Beat Estimates (Zacks) +6.86%
Nov-14-25 08:40AM	Alithya Group (ALYAF) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
Nov-13-25 09:00AM	MindWalk CTO Dr. Dirk Van Hyfte to Join Fireside Chat at AI Drug Discovery & Development Summit 2025 (Business Wire) -7.82%
08:15AM	Bitfarms Ltd. (BITF) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-11-25 05:20PM	Fathom Holdings (FTHM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Oct-28-25 08:11AM	Duos Technologies Group, Inc. (DUOT) Soars 6.5%: Is Further Upside Left in the Stock? (Zacks) -5.78%
Oct-21-25 08:28AM	MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy (Business Wire) -7.32%
Oct-15-25 07:00AM	MindWalk Appoints Dr. Thomas W. Lynch as Chief Business Officer to Accelerate Commercial Expansion (Business Wire)
Oct-09-25 07:00AM	MindWalk Announces Share Repurchase Program (Business Wire) +5.35%
Sep-23-25 07:12PM	MindWalk Holdings Corp. (HYFT) Surges with 45% Revenue Growth and Strategic AI-Focused Rebrand (Insider Monkey)
Sep-22-25 07:02AM	MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity (Business Wire) +16.18%
Sep-16-25 03:00AM	MindWalk Holdings Corp (HYFT) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com) -9.66%
Sep-15-25 10:50AM	MindWalk Holdings Corp. (HYFT) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -20.36%
08:44AM	Loading…
08:44AM	MindWalk Holdings Corp. (formerly ImmunoPrecise Antibodies) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet (Business Wire)
Sep-10-25 08:16AM	MindWalk to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2026 on September 15, 2025 (Business Wire)
Sep-03-25 08:48AM	ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to "HYFT" (Business Wire) +7.25%
Sep-02-25 08:01AM	ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York (Business Wire) -18.57%
Aug-27-25 08:22AM	ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation (Business Wire)
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +35.00%
Aug-06-25 08:00AM	ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation (Business Wire)
08:00AM	AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd. (Business Wire)
Jul-30-25 03:16AM	ImmunoPrecise Antibodies Ltd (IPA) Q4 2025 Earnings Call Highlights: Record Revenue and ... (GuruFocus.com)
Jul-29-25 09:35AM	ImmunoPrecise Antibodies Ltd. (IPA) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -14.60%
08:28AM	ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA (Business Wire)
Jul-24-25 08:22AM	ImmunoPrecise Releases New Findings Showing LENSai Quickly Flags Anti-Drug-Antibody RiskLong Before the Clinic (Business Wire) +26.92%
Jul-21-25 08:28AM	ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board (Business Wire)
Jul-16-25 08:05AM	IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025 (Business Wire) +6.04%
Jul-14-25 08:01AM	ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement (Business Wire) +33.78%
Jul-07-25 09:00AM	ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors (Business Wire) +24.43%
Jul-06-25 04:01AM	ImmunoPrecise Antibodies' LENSai Platform Achieves Breakthrough in Epitope Mapping Accuracy (Insider Monkey)
Jul-03-25 08:19AM	ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data (Business Wire) +23.58%
Jun-24-25 07:02AM	ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai Platform Powered by Patented HYFT Technology (Business Wire)
Jun-12-25 08:01AM	AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies (Business Wire) +21.57%
Jun-05-25 08:01AM	ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery (Business Wire) +22.38%
May-21-25 08:49AM	ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts (Business Wire)
May-20-25 08:28AM	ImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech Conference (Business Wire)
May-12-25 08:01AM	IPAs LENSai Platform Delivers X-RayLevel Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed (Business Wire)
Apr-11-25 08:40AM	ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai with FDA's Shift to Non-Animal Testing Methods (Business Wire) +7.56%
Apr-03-25 12:00PM	ImmunoPrecise Antibodies (IPA) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) -10.34%
Mar-28-25 12:59PM	ImmunoPrecise Antibodies Ltd. (IPA) Q3 2025 Earnings Call Transcript (Seeking Alpha) -10.97%
09:15AM	ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:01AM	ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 (Business Wire)
Mar-27-25 05:50PM	P3 Health Partners Inc. (PIII) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
Mar-13-25 07:02AM	ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics. (Business Wire) +11.48%
Mar-11-25 10:17PM	IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025 (Business Wire) +6.14% -9.04%
Mar-05-25 08:01AM	IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025 (Business Wire) +11.74%
Feb-26-25 08:01AM	IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy (Business Wire)
Feb-24-25 08:01AM	ImmunoPrecise Antibodies Announces Key Leadership Changes (Business Wire) +5.23%
Feb-20-25 08:01AM	ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period (Business Wire) -6.26%
Jan-27-25 08:01AM	ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture (Business Wire) -6.33%
Jan-23-25 07:15AM	ImmunoPrecise Antibodies develops new class of GLP-1 therapies through AI (TipRanks) -6.90%
Jan-22-25 07:02AM	IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment (Business Wire) +30.73%
Jan-17-25 08:01AM	ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation (Business Wire) -5.34%
Jan-02-25 02:55AM	ImmunoPrecise Antibodies announces resignation of CFO (TipRanks) +9.30%
Dec-31-24 07:56PM	IPA Announces Resignation of Chief Financial Officer (Business Wire)
Dec-23-24 08:30AM	ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases (Business Wire)
Dec-19-24 10:15AM	IPA to Present at The Microcap Conference 2025 (ACCESSWIRE)
Dec-10-24 08:30AM	ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 (Business Wire)
Dec-04-24 08:00AM	IPA to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference (Business Wire)
Dec-03-24 08:30AM	IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024 (Business Wire)
Nov-27-24 07:00AM	DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025 (ACCESSWIRE)
Nov-13-24 09:00AM	$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies (Business Wire)
Nov-04-24 08:01AM	ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation (Business Wire)
Oct-28-24 07:30AM	ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology (Business Wire) -15.09%
Oct-21-24 09:00AM	ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024 (Business Wire)
Oct-10-24 08:10AM	ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design (Business Wire)
Oct-09-24 03:21PM	ImmunoPrecise Antibodies Ltd (IPA) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amid ... (GuruFocus.com) -5.98%
Oct-02-24 08:00AM	ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus (Business Wire)
Sep-26-24 09:00AM	ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments (Business Wire)
Sep-16-24 09:00AM	ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 (Business Wire) -19.12%
Sep-13-24 09:01AM	Earnings To Watch: ImmunoPrecise Antibodies Ltd (IPA) Reports Q1 2025 Result (GuruFocus.com)
Sep-09-24 09:11AM	IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024 (Business Wire)
Aug-26-24 09:00AM	ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York (Business Wire)
Aug-23-24 08:00PM	ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements (Business Wire)
Aug-19-24 09:00AM	ImmunoPrecise Antibodies Successfully Engineers in silico Antibodies to Elusive Tumor Protein Using Its Patented LENSai Technology (Business Wire) -5.87%
Jul-29-24 08:30AM	ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024 (Business Wire)
Jul-23-24 07:30PM	ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year-End 2024 (Business Wire)
Jul-16-24 08:01PM	ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures (Business Wire) -7.14%
Jul-15-24 08:31AM	IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024 (Business Wire)
Jun-27-24 08:01AM	ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer (Business Wire)
Jun-25-24 07:02AM	IPAs Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai (Business Wire)
Jun-12-24 07:00AM	ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai Technology (Business Wire)
Jun-10-24 07:15AM	BioStrand, ImmunoPrecise Antibodies Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery (Business Wire) +5.05%

MindWalk Holdings Corp. is an AI-driven biotherapeutic research, technology, and scientifically robust life science company that discovers and develops customized and novel antibodies by generating proprietary and patented processes, procedures, and innovative approaches to antibody discovery, development, and production. It operates through the following geographical segments: United States of America, Europe, Canada, Australia, and Other. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Austin, TX.

CEODr. Jennifer Lynne Bath Ph.D.

Vice President of Commercial ServicesMs. Kari Graber

Vice President of Innovative SolutionsDr. Shuji Sato

Chief Financial OfficerMr. Richard Scott Areglado

Ph.D.Mr. Dirk Van Hyfte M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HYFT

MindWalk Holdings Corp

Upgrade your Finviz experience